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Abstract Tripeptidyl peptidase-I (TPP-I) is a lysosomal
peptidase which cleaves tripeptides from the N-terminus of
peptides. The function of the enzyme is unclear but its
importance is demonstrated by the fact that mutations in TPP-
I are responsible for late infantile neuronal ceroid lipofuscinosis,
a lethal lysosomal storage disease. As a step towards identifying
its natural substrates, we have used a series of synthetic peptides,
based on angiotensin-II, to explore the effects of peptide chain
length and the effects of amino acid substitutions at the P1 and
P1P positions on the rate of catalysis. With the exception of
angiotensin-(1^8) (angiotensin-II), which is a relatively poor
substrate for TPP-I, the rate of catalysis increases with
increasing chain length. Kcat/Km values increase 50-fold between
angiotensin-(1^5) and angiotensin-(1^14). TPP-I shows little
specificity for the nature of the amino acids in the P1 and P1P
positions, Kcat/Km values varying only 5-fold for a range of
substitutions. However, Pro or Lys in the P1 position and Pro in
the P1P positions are incompatible with TPP-I activity. These
observations suggest that TPP-I is a non-specific, but essential,
peptidase involved in the latter stages of lysosomal protein
degradation. ß 2001 Federation of European Biochemical So-
cieties. Published by Elsevier Science B.V. All rights reserved.
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1. Introduction
Tripeptidyl peptidase-I (TPP-I) is a lysosomal exopeptidase
which cleaves tripeptides from the N-terminus of peptides
although recent evidence suggests that the enzyme may also
possess some endopeptidase activity [1^4] The upper size limit
for peptide degradation by TPP-I appears to be about 5 kDa
[2,5]. TPP-I was originally thought to be a pepstatin-insensi-
tive carboxyl peptidase based on its homology with a family
of bacterial enzymes [6] and its resistance to inhibitors of the
four major classes of proteases [1,2]. However, recent experi-
ments suggest that TPP-I belongs to the subtilisin family of
serine proteinases but that the active site serine is relatively
unreactive [7]. TPP-I is structurally unrelated to TPP-II, a
cytoplasmic enzyme with a similar speci¢city and which is
also a member of the subtilisin family [8].
TPP-I can completely degrade small peptides, e.g. glucagon,
to tripeptides in vitro [2] and there is evidence for the involve-
ment of an endosomal acidic tripeptidyl peptidase in the he-
patic degradation of glucagon [9]. TPP-I has a ubiquitous
distribution and was originally thought to be involved in the
degradation of collagen [10]. The enzyme can release Gly-Pro-
X triplets from synthetic collagen-like polymers, and tripep-
tidyl chloromethyl ketone inhibitors of TPP-I are potent in-
hibitors of bone resorption in an in vitro test system, where
the major protein being degraded is type I collagen [1]. How-
ever, the importance of TPP-I in collagen degradation remains
unresolved.
Mutations in TPP-I are responsible for the lysosomal stor-
age disease, classical late infantile neuronal ceroid lipofusci-
nosis (CLN2, late infantile Batten disease) [6,11]. Children
with this disease are symptom free until the age of about
three. They then su¡er from progressive neurodegeneration
with associated seizures, increasing spasticity and blindness.
Death occurs around the age of ten [12]. Autopsy reveals a
dramatic loss of neuronal cells and to a lesser extent other
brain cell types. Brain cells that remain and several cell types
in other tissues contain cytoplasmic (lysosomal) storage
vesicles although the viability of non-neuronal cells does not
seem to be a¡ected. The vesicles contain auto£uorescent ce-
roid lipofuscin and other proteinaceous material. For reasons
that are not entirely clear, a major protein which accumulates
in these vesicles is subunit c of mitochondrial ATP synthase
[13]. Recent evidence suggests that TPP-I cleavage may ini-
tiate the degradation of subunit c which is then completed by
other lysosomal proteinases [14].
Little is known about the natural substrates or speci¢city of
TPP-I especially with regard to the e¡ects of the nature of the
substrate amino acids on either side of the cleavage site, or at
enzyme binding sites on the rate of peptide bond cleavage. We
now explore how increasing the peptide chain length or re-
placing amino acids on either side of the cleavage site in a
model substrate, angiotensin-II, alters the rate of catalysis. We
have chosen angiotensin-II purely as a model substrate be-
cause its degradation by TPP-I, into two readily identi¢able
and quanti¢able products, has been described previously [2].
2. Materials and methods
TPP-I was puri¢ed from pig kidneys as described previously [2].
The enzyme appeared to be homogeneous by polyacrylamide/SDS-
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gel electrophoresis and the speci¢c activity was 18 milliunit mg31
using Ala-Ala-Phe-methylcoumarylamide (Ala-Ala-Phe-NHMec) as
a substrate [1]. Peptides were purchased from Bachem (St Helens,
UK) or were synthesised by The Molecular Genetics Facility, Univer-
sity of Georgia, Athens, GA, USA.
Peptides (0.1 Wmol) were digested with TPP-I (7 Wg) in 0.1 M so-
dium acetate pH 4.0 for 1^5 h in a total volume of 200 Wl. Reactions
were terminated by adding tri£uoroacetic acid (TFA) to 0.1%. Digests
were subjected to reversed phase HPLC on a Dynamax C18-300 col-
umn (4.6U250 mm) using a 0% isocratic (10 min), 0^37.5% (60 min),
37.5^60% (15 min) and 60^0% (5 min) acetonitrile/0.1% TFA gra-
dient. Peaks were identi¢ed by comparison with standards or by ma-
trix-assisted laser desorption ionisation-time of £ight-mass spectrom-
etry (MALDI-TOF-MS) [15]. A comparison of the peak areas of the
reaction products, measured at 214 nm, with those of standards al-
lowed quantitation of the reaction rates. The values of kinetic param-
eters were calculated using the program ENZFITTER (Biosoft, Cam-
bridge, UK).
3. Results and discussion
An HPLC assay was developed to measure the kinetics of
angiotensin-(1^8) degradation by TPP-I (Fig. 1A). TPP-I deg-
radation of angiotensin-(1^8) (DRVYIHPF) produces two
fragments (DRV and YIHPF) after cleavage of the peptide
bond between Val3 and Tyr4. The identity of these two frag-
ments was determined by the elution position of standards
and mass determination by mass spectrometry. The rate of
degradation was linear with respect to time and enzyme con-
centration up to about 20% degradation of the substrate.
When the reaction between TPP-I and angiotensin-(1^8) was
performed in the presence of AAF-chloromethyl ketone, an
inhibitor of TPP-I, the production of the two degradation
products was greatly reduced (90% at 2.5 WM inhibitor)
(Fig. 1B). The pH optimum for the degradation of angioten-
sin-(1^8) was pH 4 consistent with the lysosomal localisation
of the enzyme (Fig. 2).
The e¡ect of chain length on the rate of degradation of
angiotensins was investigated using the HPLC assay (Table
1). Km varied little between the di¡erent peptide substrates
except for angiotensin-(1^14) which was hydrolysed with a
Km 3^4-fold lower than the other substrates. The main e¡ect
of varying the chain length was clearly on Vmax. Kcat and Kcat/
Km values generally increased with chain length except for
angiotensin-(1^8) where the value was considerably lower
than those for both smaller and larger peptides. Kcat/Km val-
ues increased 50-fold between angiotensin-(1^5) and angioten-
sin-(1^14). This result suggests that TPP-I has an extended
binding site which for maximum catalytic activity requires
occupancy of substrate binding sites beyond S7P. Our previous
results indicated that only peptides without tertiary structure
are substrates for TPP-I [5]. In general, peptides with an Mr
below 5 kDa have little tertiary structure. For example, glu-
cagon (Mr 3.5 kDa, extended structure) is a substrate for
TPP-I whereas IGF-I (Mr 7.5 kDa, globular structure) is
not degraded by TPP-I [5]. Similarly, both individual A and
B chains of insulin are substrates for TPP-I but the disul-
phide-bonded dimer is resistant to hydrolysis possibly because
it adopts a globular conformation which restricts access to the
active site [5]. TPP-I is likely to play a role in the degradation
of small peptides released during lysosomal proteolysis. Pep-
Fig. 1. Degradation of angiotensin-(1^8) by TPP-I. Angiotensin-(1^8) (0.1 Wmol) was incubated with TPP-I (7 Wg) for 5 h at pH 4.0 in the ab-
sence (A) or presence of 2.5 WM Ala-Ala-Phe-CH2Cl (B). Reactions were stopped by adding TFA to 0.1% and analysed by reversed phase
HPLC using a Dynamax C18-300 column (4.6U250 mm) and a 0% (10 min), 0^37.5% (60 min) and 37.5^60% (15 min) acetonitrile/0.1% TFA
gradient. The elution position of fragments was compared to that of standards. Digestion of angiotensin-(1^8) (DRVYIHPF) yields two frag-
ments, angiotensin-(1^3) (DRV) and angiotensin-(4^8) (YIHPF).
FEBS 25021 29-6-01
M.J. Warburton, F. Bernardini/FEBS Letters 500 (2001) 145^148146
tides must be degraded to di- or tripeptides or amino acids
before they can be transported out of the lysosomes [16].
Rapid degradation of larger peptides would provide abundant
di- and tripeptides for degradation by cytoplasmic peptidases
which are present in high levels in many tissues.
TPP-I requires that substrates have an unblocked N-termi-
nus. Neither acetyl-angiotensin-(1^8) or acetyl-angiotensin-
(1^8)-amide were substrates for TPP-I (Table 1). Angioten-
sin-(1^8)-amide was a substrate for TPP-I with a Kcat/Km
value 2.5-fold greater than observed for the hydrolysis of
angiotensin-(1^8) but still below the Kcat/Km values for the
hydrolysis of the other peptides. The increased catalytic rate
for the amide suggests that a carboxylic acid group at P5P
reduces the rate of catalysis. (3,5-diiodo-Tyr4)-angiotensin-II
was not hydrolysed by TPP-I possibly because of steric hin-
drance by the two bulky iodines.
The reasons for the comparatively slow rate of degradation
of angiotensin-(1^8) by TPP-I are unclear, especially as angio-
tensin-(1^8) is possibly a physiological substrate for TPP-I.
Evidence has been presented for the involvement of an acidic
tripeptidyl peptidase in the metabolism of small peptide hor-
mones which undergo receptor-mediated endocytosis [9]. An-
giotensin-(1^8) complexed with its AT1-type receptor is rap-
idly internalised by endocytosis in a process which is
independent of G-protein coupling [17]. A decreased sensitiv-
ity to proteolysis might prolong the generation of the intra-
cellular signalling process which involves coupling of recep-
tors to G-proteins. It has recently been demonstrated that
signal transduction, through the JAK^STAT pathway, con-
tinues after internalisation of growth hormone^receptor com-
plexes into endosomes [18].
As angiotensin-(1^8) is potentially a physiological substrate
for TPP-I, we investigated the e¡ects of amino acid substitu-
tions at positions 3 and 4 on its rate of degradation (Table 2).
Substitution of either Val3 or Tyr4 with Pro abolished the
ability of TPP-I to hydrolyse the substrate. Synthetic sub-
strates with a Pro in the P1 position and a form of bovine
growth hormone with the N-terminus Ala-Met-Pro have been
shown to be resistant to TPP-I [19]. Studies on the degrada-
tion of synthetic peptides corresponding to exposed regions of
subunit c of ATP synthase have demonstrated that peptides
with a Pro in the P1 position are resistant to hydrolysis by
TPP-I [14]. TPP-II is also unable to hydrolyse peptide bonds
with a Pro in either the P1 or P1P position [20]. Substitution of
Val3 with Lys also resulted in a TPP-I resistant peptide unlike
substitution of Tyr4 with Lys which resulted in a peptide
which could be hydrolysed but with a reduced Kcat/Km com-
pared to the wild-type angiotensin-(1^8). A negatively charged
amino acid (glutamate) at position 3 did not impair digestion
of the peptide. The inability of TPP-I to hydrolyse synthetic
tripeptidyl-aminomethylcoumarin substrates with a positively
charged amino acid in the P1 position has been noted previ-
ously [1,2]. Overall, Kcat/Km varied by no more than 5-fold
throughout the series of peptides. A Tyr or Ser at position 3
and a Ser at position 4 gave the highest rates of catalysis.
These results are consistent with a role for TPP-I as a non-
speci¢c lysosomal peptidase which generates tripeptides from
the breakdown products produced by lysosomal proteinases,
e.g. cathepsins B and L. For example, the degradation of
glucagon by cathepsin L produces peptides with lengths of
2, 7, 8 and 12 amino acids [21]. TPP-I might also be involved
directly in the degradation of small peptide hormones brought
into cells by receptor-mediated endocytosis. The tripeptides
produced would be further degraded by lysosomal peptidases
or transported into the cytoplasm for degradation to amino
acids. TPP-I is presumably essential for lysosomal protein
degradation as the absence of this activity results in a severe
lysosomal storage disease.
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Fig. 2. pH activity pro¢le for the degradation of angiotensin-(1^8)
by TPP-I. Angiotensin-(1^8) was incubated with TPP-I over the pH
range 2.5^9. Reaction mixtures were subjected to reversed phase
HPLC to determine the extent of angiotensin-(1^8) degradation.
The bu¡ers used were 0.1 M sodium citrate (pH 2.5^4), 0.1 M so-
dium acetate (pH 4^6) and sodium phosphate (pH 6^9) all contain-
ing 0.5 M NaCl.
Table 1
Kinetic parameters for the hydrolysis of (A) angiotensin-derived peptides of various lengths and (B) derivatives of angiotensin-(1^8)
Peptide Km (mM) Kcat (min31) Kcat/Km (min31 mM31)
(A)
DRVYI angiotensin-(1^5) 0.14 4.6 32.9
DRVYIH angiotensin-(1^6) 0.14 11.7 81.8
DRVYIHP angiotensin-(1^7) 0.13 11.9 89.5
DRVYIHPF angiotensin-(1^8) 0.19 0.8 4.3
DRVYIHPFHL angiotensin-(1^10) 0.13 39.4 303
DRVYIHPFHLLYYS angiotensin-(1^14) 0.04 61.4 1639
(B)
Ac-DRVYIHPF nha
Ac-DRVYIHPF-NH2 nha
DRVYIHPF-NH2 0.16 1.8 11.3
DRV(diiodo-Y)IHPF nha
anh = not hydrolysed.
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Table 2
Kinetic parameters for the hydrolysis of angiotensin-(1^8) with amino acid substitutions at positions 3 and 4
Peptide Km (mM) Kcat (min31) Kcat/Km (min31 mM31)
DRV-YIHPF 0.19 0.82 4.32
DRK-YIHPF nha
DRY-YIHPF 0.21 2.69 12.70
DRS-YIHPF 0.08 0.81 10.70
DRE-YIHPF 0.16 0.59 3.81
DRG-YIHPF 0.12 0.68 5.75
DRP-YIHPF nha
DRV-KIHPF 0.19 0.62 3.36
DRV-VIHPF 0.19 1.55 8.13
DRV-SIHPF 0.15 2.49 16.70
DRV-EIHPF 0.10 0.76 8.03
DRV-GIHPF 0.13 1.22 9.49
DRV-PIHPF nha
anh = not hydrolysed.
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